

# Tsutomu Takeuchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7713293/publications.pdf>

Version: 2024-02-01

599  
papers

28,069  
citations

8755

75  
h-index

9345

143  
g-index

659  
all docs

659  
docs citations

659  
times ranked

18809  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
3	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.9	1,114
4	Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 1761-1769.	6.7	751
5	Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1162-1167.	0.9	674
6	Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 189-194.	0.9	382
7	Translating IL-6 biology into effective treatments. <i>Nature Reviews Rheumatology</i> , 2020, 16, 335-345.	8.0	369
8	Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. <i>Modern Rheumatology</i> , 2009, 19, 12-19.	1.8	312
9	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. <i>Arthritis and Rheumatology</i> , 2017, 69, 506-517.	5.6	310
10	Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1580-1584.	0.9	289
11	Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. <i>Journal of Rheumatology</i> , 2007, 34, 322-31.	2.0	266
12	Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1286-1291.	0.9	251
13	Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. <i>Arthritis and Rheumatism</i> , 2001, 44, 550-560.	6.7	242
14	Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. <i>BioDrugs</i> , 2017, 31, 299-316.	4.6	241
15	Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. <i>Blood</i> , 2008, 112, 635-643.	1.4	230
16	Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. <i>Modern Rheumatology</i> , 2009, 19, 12-19.	1.8	228
17	Serum Indicators for the Diagnosis of Pneumocystis Pneumonia. <i>Chest</i> , 2007, 131, 1173-1180.	0.8	217
18	Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 315.	7.4	210

#	ARTICLE	IF	CITATIONS
19	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. <i>Journal of Rheumatology</i> , 2019, 46, 7-18.	2.0	207
20	Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. <i>Journal of Rheumatology</i> , 2005, 32, 1719-26.	2.0	189
21	Abnormal protein profiles in tears with dry eye syndrome. <i>American Journal of Ophthalmology</i> , 2003, 136, 291-299.	3.3	185
22	Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan. <i>Journal of Rheumatology</i> , 2014, 41, 15-23.	2.0	174
23	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 165-174.	0.9	173
24	Brief Report: Number of Circulating Follicular Helper 2 T Cells Correlates With IgG4 and Interleukin-4 Levels and Plasmablast Numbers in IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2015, 67, 2476-2481.	5.6	168
25	Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan. <i>Journal of Rheumatology</i> , 2009, 36, 898-906.	2.0	167
26	Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2148-2151.	0.9	166
27	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
28	Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (denosumab) in patients with rheumatoid arthritis on methotrexate to validate inhibitory effect on bone erosion (DRIVE) a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 983-990.	0.9	157
29	<i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis treated with infliximab: A retrospective review and case-control study of 21 patients. <i>Arthritis and Rheumatism</i> , 2009, 61, 305-312.	6.7	146
30	Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. <i>Journal of Rheumatology</i> , 2011, 38, 1258-1264.	2.0	141
31	Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. <i>Nature Communications</i> , 2018, 9, 2755.	12.8	140
32	Enhanced IgG4 production by follicular helper 2 cells and the involvement of follicular helper 1 cells in the pathogenesis of IgG4-related disease. <i>Arthritis Research and Therapy</i> , 2016, 18, 167.	3.5	139
33	Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1042-1055.	5.6	135
34	Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1208-1215.	0.9	131
35	Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2007, 17, 451-458.	1.8	130
36	Tocilizumab in patients with adult-onset still disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1720-1729.	0.9	129

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 1607-1620.	5.6	126
38	Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1057-1064.	0.9	125
39	Induction of suppression following autologous mixed lymphocyte reaction; role of a novel 2H4 antigen. <i>European Journal of Immunology</i> , 1987, 17, 97-103.	2.9	117
40	SERUM LEVELS OF IFN-INDUCIBLE PROTEIN-10 RELATING TO THE ACTIVITY OF SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Cytokine</i> , 2000, 12, 1561-1565.	3.2	117
41	Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. <i>Arthritis Research and Therapy</i> , 2016, 18, 34.	3.5	117
42	Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. <i>Modern Rheumatology</i> , 2015, 25, 514-521.	1.8	109
43	Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 1069-1072.	1.9	108
44	A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2007, 17, 191-197.	1.8	107
45	Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. <i>Nature Immunology</i> , 2019, 20, 1631-1643.	14.5	107
46	Expression of cell adhesion molecules in the salivary and lacrimal glands of Sjogren's syndrome. <i>Journal of Clinical Laboratory Analysis</i> , 1993, 7, 180-187.	2.1	105
47	Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. <i>Modern Rheumatology</i> , 2014, 24, 17-25.	1.8	105
48	Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 3 2019, 78, 899-907.	0.9	105
49	Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. <i>Modern Rheumatology</i> , 2009, 19, 478-487.	1.8	104
50	The Multicenter Study of a New Assay for Simultaneous Detection of Multiple Anti-Aminoacyl-tRNA Synthetases in Myositis and Interstitial Pneumonia. <i>PLoS ONE</i> , 2014, 9, e85062.	2.5	104
51	Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 817-824.	0.9	102
52	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients. <i>Modern Rheumatology</i> , 2014, 24, 390-398.	1.8	100
53	The Japanese experience with biologic therapies for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2010, 6, 644-652.	8.0	99
54	Remarkable Genetic Polymorphism among <i>Entamoeba histolytica</i> Isolates from a Limited Geographic Area. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4081-4090.	3.9	97

#	ARTICLE	IF	CITATIONS
55	CD14 <sup>bright</sup> CD16 <sup>+</sup> intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 28.	3.5	97
56	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2011, 21, 343-351.	1.8	95
57	Efficacy and safety of peficitinib (ASPO15K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1305-1319.	0.9	95
58	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 75-83.	0.9	94
59	A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2007, 17, 191-197.	1.8	92
60	Conjunctival Epithelium Expression of HLA-DR in Dry Eye Patients. <i>Ophthalmologica</i> , 1999, 213, 16-19.	1.9	90
61	Peripheral blood CD4 <sup>+</sup> CD25 <sup>+</sup> CD127 <sup>low</sup> regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. <i>Arthritis Research and Therapy</i> , 2015, 17, 10.	3.5	90
62	Geographic Diversity among Genotypes of <i>Entamoeba histolytica</i> Field Isolates. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3748-3756.	3.9	88
63	Clinical and Radiological Features of Pneumocystis Pneumonia in Patients with Rheumatoid Arthritis, in comparison with Methotrexate Pneumonitis and Pneumocystis Pneumonia in Acquired Immunodeficiency Syndrome: A Multicenter Study. <i>Internal Medicine</i> , 2008, 47, 915-923.	0.7	88
64	The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-blind, Placebo/Active-controlled, Dose-ranging Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 2591-2600.	5.6	86
65	Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2007, 17, 451-458.	1.8	86
66	Efficacy and safety of peficitinib (ASPO15K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1320-1332.	0.9	85
67	A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 37-44.	2.0	84
68	Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 536-543.	0.9	82
69	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. <i>Modern Rheumatology</i> , 2012, 22, 498-508.	1.8	81
70	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1917-1923.	0.9	81
71	Multiomeric disease signatures converge to cytotoxic CD8 T cells in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1458-1466.	0.9	81
72	TCR zeta chain lacking exon 7 in two patients with systemic lupus erythematosus. <i>International Immunology</i> , 1998, 10, 911-921.	4.0	80

#	ARTICLE	IF	CITATIONS
73	Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016, 26, 491-498.	1.8	80
74	Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF- $\alpha$ monoclonal antibody, infliximab. <i>Rheumatology</i> , 2008, 47, 780-788.	1.9	79
75	Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. <i>Rheumatology</i> , 2011, 50, 1908-1915.	1.9	78
76	Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study. <i>Journal of Rheumatology</i> , 2011, 38, 1585-1592.	2.0	75
77	Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2016, 43, 1825-1831.	2.0	74
78	Follicular helper T cells in the pathogenesis of IgG4-related disease. <i>Rheumatology</i> , 2018, 57, 236-245.	1.9	72
79	Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. <i>Modern Rheumatology</i> , 2009, 19, 478-487.	1.8	72
80	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.9	71
81	Brief Report: Leucine <sup>2</sup> -Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti-Interleukin-6 Biologic Therapy in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2056-2060.	5.6	71
82	Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 335-343.	0.9	71
83	Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. <i>RMD Open</i> , 2017, 3, e000363.	3.8	70
84	Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2015, 25, 817-824.	1.8	69
85	Clinical and Radiological Features of Acute-Onset Diffuse Interstitial Lung Diseases in Patients with Rheumatoid Arthritis Receiving Treatment with Biological Agents: Importance of &Pneumocystis& Pneumonia in Japan Revealed by a Multicenter Study. <i>Internal Medicine</i> , 2011, 50, 305-313.	0.7	68
86	Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. <i>Rheumatology</i> , 2011, 50, 1268-1274.	1.9	68
87	Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort. <i>Rheumatology</i> , 2012, 51, 1846-1854.	1.9	68
88	Interaction of KLRG1 with E-cadherin: New functional and structural insights. <i>European Journal of Immunology</i> , 2008, 38, 3354-3364.	2.9	66
89	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 171-178.	0.9	66
90	Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). <i>Modern Rheumatology</i> , 2011, 21, 122-133.	1.8	65

#	ARTICLE	IF	CITATIONS
91	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 878-891.	5.6	64
92	Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. <i>Modern Rheumatology</i> , 2005, 15, 4-8.	1.8	63
93	Reduction of plasma IL-6 but not TNF- $\alpha$ by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. <i>Clinical Rheumatology</i> , 2013, 32, 1661-1666.	2.2	63
94	Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. <i>Rheumatology International</i> , 2016, 36, 881-889.	3.0	63
95	RANKL: A therapeutic target for bone destruction in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018, 28, 9-16.	1.8	63
96	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008, 18, 146-152.	1.8	61
97	Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. <i>Arthritis Research and Therapy</i> , 2019, 21, 103.	3.5	61
98	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1290-1297.	0.9	61
99	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. <i>Modern Rheumatology</i> , 2010, 20, 531-538.	1.8	60
100	Multi-dimensional analysis identified rheumatoid arthritis-driving pathway in human T cell. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1346-1356.	0.9	60
101	Overview of lupus nephritis management guidelines and perspective from Asia. <i>Nephrology</i> , 2014, 19, 11-20.	1.6	59
102	Mutations in T cell Receptor $\alpha$ Chain mRNA of Peripheral T cells from Systemic Lupus Erythematosus Patients. <i>Journal of Autoimmunity</i> , 1998, 11, 381-385.	6.5	58
103	Guidelines for the proper use of etanercept in Japan. <i>Modern Rheumatology</i> , 2006, 16, 63-67.	1.8	58
104	Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. <i>Biochemical and Biophysical Research Communications</i> , 2009, 387, 261-265.	2.1	58
105	Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2021, 20, 102884.	5.8	57
106	TCR $\alpha$ mRNA with an Alternatively Spliced 3'-Untranslated Region Detected in Systemic Lupus Erythematosus Patients Leads to the Down-Regulation of TCR $\alpha$ and TCR/CD3 Complex. <i>Journal of Immunology</i> , 2003, 171, 2496-2503.	0.8	56
107	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). <i>Modern Rheumatology</i> , 2007, 17, 28-32.	1.8	56
108	Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. <i>Leukemia and Lymphoma</i> , 2012, 53, 616-623.	1.3	56

#	ARTICLE	IF	CITATIONS
109	Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2001-2008.	0.9	55
110	Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2011, 13, R170.	3.5	54
111	Elevated Levels of Pentraxin 3 in Systemic Sclerosis: Associations With Vascular Manifestations and Defective Vasculogenesis. <i>Arthritis and Rheumatology</i> , 2015, 67, 498-507.	5.6	54
112	Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. <i>Modern Rheumatology</i> , 2017, 27, 237-245.	1.8	54
113	Safety, pharmacokinetics, and efficacy of E6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018, 28, 58-65.	1.8	54
114	Characteristics and prognosis of IgG4-related periaortitis/periarteritis: A systematic literature review. <i>Autoimmunity Reviews</i> , 2019, 18, 102354.	5.8	54
115	Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. <i>Lupus</i> , 2010, 19, 162-169.	1.6	53
116	Primary and secondary surveys on epidemiology of Sjögren's syndrome in Japan. <i>Modern Rheumatology</i> , 2014, 24, 464-470.	1.8	53
117	Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. <i>Arthritis Research and Therapy</i> , 2015, 17, 74.	3.5	53
118	Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. <i>Modern Rheumatology</i> , 2016, 26, 15-23.	1.8	53
119	Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). <i>Modern Rheumatology</i> , 2011, 21, 122-133.	1.8	52
120	Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1488-1495.	0.9	51
121	Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 602-611.	0.9	51
122	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. <i>Lancet Rheumatology</i> , The, 2020, 2, e347-e357.	3.9	51
123	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2011, 21, 343-351.	1.8	51
124	High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. <i>Arthritis Research and Therapy</i> , 2017, 19, 194.	3.5	50
125	Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. <i>Journal of Clinical Medicine</i> , 2019, 8, 831.	2.4	50
126	CD11 molecule defines two types of suppressor cells within the T8+ population. <i>Cellular Immunology</i> , 1988, 111, 398-409.	3.0	49

#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , 2014, 24, 715-724.	1.8	49
128	Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. <i>Leukemia and Lymphoma</i> , 2018, 59, 1143-1152.	1.3	49
129	Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2007, 26, 1585-1589.	2.2	48
130	Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. <i>Arthritis Research and Therapy</i> , 2017, 19, 208.	3.5	48
131	Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001095.	3.8	48
132	Critical role of CD4+CD25+ regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. <i>Experimental Hematology</i> , 2012, 40, 279-289.	0.4	47
133	Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2016, 18, 106.	3.5	47
134	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. <i>Modern Rheumatology</i> , 2012, 22, 498-508.	1.8	47
135	Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. <i>Modern Rheumatology</i> , 2011, 21, 10-15.	1.8	46
136	<i>Pneumocystis jirovecii</i> pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. <i>Modern Rheumatology</i> , 2012, 22, 849-858.	1.8	46
137	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). <i>Modern Rheumatology</i> , 2007, 17, 28-32.	1.8	46
138	Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 1265-1268.	1.9	45
139	IgG4-related fibrosing mediastinitis diagnosed with computed tomography-guided percutaneous needle biopsy. <i>Medicine (United States)</i> , 2018, 97, e10935.	1.0	45
140	Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. <i>Rheumatology</i> , 2017, 56, 940-946.	1.9	44
141	Clinical practice guideline for Sjögren's syndrome 2017. <i>Modern Rheumatology</i> , 2018, 28, 383-408.	1.8	44
142	IgG4-Related Disease: Beyond Glucocorticoids. <i>Drugs and Aging</i> , 2018, 35, 275-287.	2.7	44
143	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. <i>Modern Rheumatology</i> , 2020, 30, 36-43.	1.8	44
144	Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients. <i>Clinical and Experimental Immunology</i> , 2002, 129, 160-168.	2.6	43

#	ARTICLE	IF	CITATIONS
145	Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy. <i>International Immunology</i> , 2006, 18, 1189-1196.	4.0	43
146	The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study. <i>Modern Rheumatology</i> , 2015, 25, 401-404.	1.8	43
147	Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1268-1275.	0.9	43
148	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008, 18, 146-152.	1.8	43
149	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. <i>Modern Rheumatology</i> , 2010, 20, 531-538.	1.8	43
150	T cell abnormalities in systemic lupus erythematosus. <i>Autoimmunity</i> , 2005, 38, 339-346.	2.6	41
151	Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. <i>Rheumatology</i> , 2020, 59, 3303-3313.	1.9	41
152	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008, 18, 447-454.	1.8	40
153	Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , 2014, 24, 552-560.	1.8	40
154	Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. <i>Modern Rheumatology</i> , 2016, 26, 80-86.	1.8	40
155	Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2017, 19, 218.	3.5	40
156	Effectiveness of tocilizumab in Behcet's disease: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 797-804.	3.4	40
157	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 184-192.	0.9	40
158	Cellular mechanism of DNA-specific antibody synthesis by lymphocytes from systemic lupus erythematosus patients. <i>Arthritis and Rheumatism</i> , 1984, 27, 766-773.	6.7	39
159	Altered Distribution of Aquaporin 5 and its C-Terminal Binding Protein in the Lacrimal Glands of a Mouse Model for Sjögren's Syndrome. <i>Current Eye Research</i> , 2008, 33, 621-629.	1.5	39
160	Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. <i>Rheumatology</i> , 2015, 54, 683-691.	1.9	39
161	Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. <i>Rheumatology</i> , 2021, 60, 5247-5256.	1.9	39
162	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). <i>Modern Rheumatology</i> , 2012, 22, 327-338.	1.8	38

#	ARTICLE	IF	CITATIONS
163	Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. <i>Arthritis Research and Therapy</i> , 2016, 18, 159.	3.5	38
164	Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study. <i>Modern Rheumatology</i> , 2015, 25, 21-30.	1.8	37
165	Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis. <i>Cytokine</i> , 2016, 78, 87-93.	3.2	37
166	Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome with other sets of criteria in Japanese patients. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1980-1985.	0.9	37
167	Distinct features distinguishing IgG4-related disease from multicentric Castleman's disease. <i>RMD Open</i> , 2017, 3, e000432.	3.8	37
168	Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. <i>Modern Rheumatology</i> , 2011, 21, 10-15.	1.8	37
169	In Vitro Immune Response of SLE Lymphocytes.. <i>Scandinavian Journal of Immunology</i> , 1982, 16, 369-377.	2.7	36
170	A Splice Variant of the TCR $\beta$ mRNA Lacking Exon 7 Leads to the Down-Regulation of TCR $\beta$ , the TCR/CD3 Complex, and IL-2 Production in Systemic Lupus Erythematosus T Cells. <i>Journal of Immunology</i> , 2005, 174, 3518-3525.	0.8	36
171	Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review. <i>Clinical Rheumatology</i> , 2012, 31, 569-574.	2.2	36
172	Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017, 84, 379-380.	1.6	36
173	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1348-1356.	0.9	36
174	Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. <i>Modern Rheumatology</i> , 2018, 28, 583-591.	1.8	36
175	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374.	3.8	36
176	Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 945-947.	0.9	35
177	Polarization diversity of human CD4+ stem cell memory T cells. <i>Clinical Immunology</i> , 2015, 159, 107-117.	3.2	35
178	Interleukin-4 contributes to the shift of balance of IgG subclasses toward IgG4 in IgG4-related disease. <i>Cytokine</i> , 2018, 110, 416-419.	3.2	35
179	Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. <i>Journal of Clinical Medicine</i> , 2019, 8, 1394.	2.4	35
180	Functional characterization of the CD45R (2H4) molecule on CD8 (T8) cells in the autologous mixed lymphocyte reaction system. <i>European Journal of Immunology</i> , 1989, 19, 747-755.	2.9	34

#	ARTICLE	IF	CITATIONS
181	Recent Advances in the Treatment of Interstitial Lung Disease in Patients with Polymyositis/Dermatomyositis. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2006, 6, 409-415.	1.2	34
182	Overview of lupus nephritis management guidelines and perspective from Asia. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 625-636.	1.9	34
183	Discordance in Global Assessments Between Patient and Estimator in Patients with Newly Diagnosed Rheumatoid Arthritis: Associations with Progressive Joint Destruction and Functional Impairment. <i>Journal of Rheumatology</i> , 2014, 41, 1061-1066.	2.0	34
184	Association Between Reappearance of Myeloperoxidase-Associated Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1626-1633.	5.6	34
185	Abnormal expression and function of Fas ligand of lachrymal glands and peripheral blood in Sjögren's syndrome patients with enlarged exocrine glands. <i>Clinical and Experimental Immunology</i> , 2002, 129, 177-182.	2.6	33
186	AXENIC CULTIVATION OF ENTAMOEBA DISPAR IN NEWLY DESIGNED YEAST EXTRACT-IRON-GLUCONIC ACID-DIHYDROXYACETONE-SERUM MEDIUM. <i>Journal of Parasitology</i> , 2005, 91, 1-4.	0.7	33
187	Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. <i>Circulation Journal</i> , 2018, 82, 546-554.	1.6	33
188	Platelet CXCL4 mediates neutrophil extracellular traps formation in ANCA-associated vasculitis. <i>Scientific Reports</i> , 2021, 11, 222.	3.3	33
189	Critical Role of the Fifth Domain of E-Cadherin for Heterophilic Adhesion with $\beta$ 7, But Not for Homophilic Adhesion. <i>Journal of Immunology</i> , 2005, 175, 1014-1021.	0.8	32
190	Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. <i>Clinical and Experimental Immunology</i> , 2006, 144, 335-341.	2.6	32
191	Mice Lacking Inositol 1,4,5-Trisphosphate Receptors Exhibit Dry Eye. <i>PLoS ONE</i> , 2014, 9, e99205.	2.5	32
192	Granulomatous amoebic encephalitis caused by <i>Acanthamoeba</i> in a patient with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 1998, 17, 329-332.	2.2	31
193	A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. <i>Modern Rheumatology</i> , 2009, 19, 273-282.	1.8	31
194	IgG4-positive multi-organ lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialadenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation. <i>Rheumatology</i> , 2010, 49, 1789-1791.	1.9	31
195	A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2013, 23, 623-633.	1.8	31
196	CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1386-1387.	0.9	31
197	Guidelines for the proper use of etanercept in Japan. <i>Modern Rheumatology</i> , 2006, 16, 63-67.	1.8	31
198	The 2H4 molecule but not the T3-receptor complex is involved in suppressor inducer signals in the AMLR system. <i>Cellular Immunology</i> , 1987, 107, 107-114.	3.0	30

#	ARTICLE	IF	CITATIONS
199	Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. <i>Journal of Gastroenterology</i> , 2012, 47, 540-552.	5.1	30
200	Secukinumab after anti-tumour necrosis factor- $\hat{\pm}$ therapy: a phase III study in active rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 276-281.	1.1	30
201	Biomarkers as a treatment guide in rheumatoid arthritis. <i>Clinical Immunology</i> , 2018, 186, 59-62.	3.2	30
202	Up-regulation of $\hat{\pm}$ $\hat{\pm}$ 27, a novel integrin adhesion molecule, on T cells from systemic lupus erythematosus patients with specific epithelial involvement. <i>Arthritis and Rheumatism</i> , 1998, 41, 1456-1463.	6.7	29
203	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. <i>Modern Rheumatology</i> , 2012, 22, 814-822.	1.8	29
204	Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1583-1585.	0.9	29
205	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008, 18, 447-454.	1.8	29
206	Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2014, 24, 8-16.	1.8	28
207	Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. <i>Modern Rheumatology</i> , 2005, 15, 4-8.	1.8	28
208	A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. <i>Modern Rheumatology</i> , 2009, 19, 273-282.	1.8	28
209	Suppression of rheumatoid factor synthesis by antiidiotypic antibody in rheumatoid arthritis patients with cross-reactive idiotypes. <i>Arthritis and Rheumatism</i> , 1985, 28, 873-881.	6.7	27
210	Elucidation of apoptosis induced by serum deprivation in cultured conjunctival epithelial cells. <i>British Journal of Ophthalmology</i> , 2006, 90, 760-764.	3.9	27
211	Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. <i>Rheumatology International</i> , 2009, 29, 431-436.	3.0	27
212	Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. <i>Rheumatology International</i> , 2011, 31, 757-763.	3.0	27
213	Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. <i>Rheumatology</i> , 2014, 53, 904-913.	1.9	27
214	Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis. <i>Arthritis Research and Therapy</i> , 2019, 21, 304.	3.5	27
215	CD30 and the NPM-ALK fusion protein (p80) are differentially expressed between peripheral blood and bone marrow in primary small cell variant of anaplastic large cell lymphoma. <i>American Journal of Hematology</i> , 2002, 69, 200-204.	4.1	26
216	Efficacy and safety of bucillamine, ad-penicillamine analogue, in patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2006, 16, 85-91.	1.8	26

#	ARTICLE	IF	CITATIONS
217	Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. <i>Modern Rheumatology</i> , 2007, 17, 92-97.	1.8	26
218	Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 1354-1362.	3.4	26
219	Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naïve patients with rheumatoid arthritis: The FIRST Bio study. <i>Modern Rheumatology</i> , 2017, 27, 217-226.	1.8	26
220	Identification of novel genes associated with dysregulation of B cells in patients with primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2020, 22, 153.	3.5	26
221	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). <i>Modern Rheumatology</i> , 2012, 22, 327-338.	1.8	26
222	<i>Pneumocystis jirovecii</i> pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. <i>Modern Rheumatology</i> , 2012, 22, 849-858.	1.8	26
223	AN OUTBREAK OF AMEBIASIS IN AN INSTITUTION FOR THE MENTALLY RETARDED IN JAPAN. <i>Japanese Journal of Medical Science and Biology</i> , 1989, 42, 63-76.	0.4	26
224	Quantitative analysis of lacrimal gland function, apoptotic figures, Fas and Fas ligand expression of lacrimal glands in dry eye patients. <i>Experimental Eye Research</i> , 2003, 76, 233-240.	2.6	25
225	Critical role of dendritic cells in determining the Th1/Th2 balance upon <i>Leishmania major</i> infection. <i>International Immunology</i> , 2008, 20, 337-343.	4.0	25
226	Cytokine profiles of bronchoalveolar lavage fluid in patients with pneumocystis pneumonia. <i>Microbiology and Immunology</i> , 2010, 54, no-no.	1.4	25
227	Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 299-304.	0.9	25
228	CD3 <sup>+</sup> defects in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, i78-i81.	0.9	25
229	Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. <i>Modern Rheumatology</i> , 2013, 23, 226-235.	1.8	25
230	Secukinumab in Active Rheumatoid Arthritis after Anti-TNF $\alpha$ Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study. <i>Rheumatology and Therapy</i> , 2017, 4, 475-488.	2.3	25
231	Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate. <i>Arthritis Care and Research</i> , 2020, 72, 1112-1121.	3.4	25
232	Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells. <i>Cytokine</i> , 2008, 44, 44-48.	3.2	24
233	Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity—results from the ENCOURAGE study, a prospective, international, multicenter randomized study. <i>Modern Rheumatology</i> , 2016, 26, 651-661.	1.8	24
234	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 425-433.	1.9	24

#	ARTICLE	IF	CITATIONS
235	Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 521-525.	3.4	24
236	Evaluation of human conjunctival epithelium by a combination of brush cytology and flow cytometry: An approach to the quantitative technique. <i>Diagnostic Cytopathology</i> , 1997, 17, 456-460.	1.0	23
237	Revolutionary Change in Rheumatoid Arthritis Management with Biological Therapy. <i>Keio Journal of Medicine</i> , 2011, 60, 75-81.	1.1	23
238	Anti-citrullinated peptide/protein antibody (ACPA)-negative RA shares a large proportion of susceptibility loci with ACPA-positive RA: a meta-analysis of genome-wide association study in a Japanese population. <i>Arthritis Research and Therapy</i> , 2015, 17, 104.	3.5	23
239	Methotrexate-associated Intravascular Large B-cell Lymphoma in a Patient with Rheumatoid Arthritis. <i>Internal Medicine</i> , 2016, 55, 1661-1665.	0.7	23
240	Safety of Biologic Agents in Elderly Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 1984-1988.	2.0	23
241	Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head. <i>Scientific Reports</i> , 2017, 7, 15035.	3.3	23
242	Aryl hydrocarbon receptor signals attenuate lung fibrosis in the bleomycin-induced mouse model for pulmonary fibrosis through increase of regulatory T cells. <i>Arthritis Research and Therapy</i> , 2020, 22, 20.	3.5	23
243	A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2013, 23, 623-633.	1.8	23
244	Thrombotic thrombocytopenic purpura in two patients with systemic lupus erythematosus: Clinical significance of anti-platelet antibodies. <i>Clinical Immunology and Immunopathology</i> , 1990, 57, 125-136.	2.0	22
245	Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus. <i>Rheumatology</i> , 2008, 48, 198-199.	1.9	22
246	Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients. <i>Modern Rheumatology</i> , 2013, 23, 219-225.	1.8	22
247	Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment. <i>Clinical Rheumatology</i> , 2018, 37, 1107-1110.	2.2	22
248	Entamoeba dispar: Cultivation with Sterilized Crithidia fasciculata. <i>Journal of Eukaryotic Microbiology</i> , 1998, 45, 3S-8S.	1.7	21
249	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial. <i>Modern Rheumatology</i> , 2011, 21, 458-468.	1.8	21
250	Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 115-125.	3.7	21
251	Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases. <i>RMD Open</i> , 2015, 1, e000162.	3.8	21
252	Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1-year outcomes of the HOPEFUL-2 study. <i>RMD Open</i> , 2016, 2, e000189.	3.8	21

#	ARTICLE	IF	CITATIONS
253	Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study. <i>Advances in Therapy</i> , 2017, 34, 686-702.	2.9	21
254	Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment. <i>Frontiers in Immunology</i> , 2018, 9, 621.	4.8	21
255	Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. <i>Arthritis Research and Therapy</i> , 2020, 22, 47.	3.5	21
256	Anti-centromere antibodies target centromere-associated kinetochore macrocomplex: a comprehensive autoantigen profiling. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 651-659.	0.9	21
257	Peripheral TIGIT+ T Follicular Helper Cells That Produce High Levels of Interleukin-21 via OX40 Represent Disease Activity in IgG4-Related Disease. <i>Frontiers in Immunology</i> , 2021, 12, 651357.	4.8	21
258	Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. <i>Modern Rheumatology</i> , 2007, 17, 92-97.	1.8	21
259	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. <i>Modern Rheumatology</i> , 2012, 22, 814-822.	1.8	21
260	Primary natural killer cell lymphoma of the lacrimal sac. <i>Annals of Hematology</i> , 2001, 80, 607-610.	1.8	20
261	Immunological Characteristics of Patients with Vernal Keratoconjunctivitis. <i>Japanese Journal of Ophthalmology</i> , 2002, 46, 244-248.	1.9	20
262	No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. <i>Modern Rheumatology</i> , 2013, 23, 945-952.	1.8	20
263	A Paradigm Shift in Rheumatoid Arthritis over the Past Decade. <i>Internal Medicine</i> , 2014, 53, 1895-1903.	0.7	20
264	Tofeforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies. <i>Journal of Rheumatology</i> , 2016, 43, 1637-1642.	2.0	20
265	Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 522-532.	2.7	20
266	Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: Results from a Japanese multi-institutional retrospective study. <i>Modern Rheumatology</i> , 2022, 32, 16-23.	1.8	20
267	Clinical Significance of Cartilage Biomarkers for Monitoring Structural Joint Damage in Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy. <i>PLoS ONE</i> , 2012, 7, e37447.	2.5	20
268	Flow Cytometric Analysis of Surface Antigens on Human Conjunctival Epithelial Cells. <i>Ophthalmic Research</i> , 1997, 29, 103-109.	1.9	19
269	Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. <i>Modern Rheumatology</i> , 2013, 23, 1211-1220.	1.8	19
270	Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. <i>Modern Rheumatology</i> , 2014, 24, 26-32.	1.8	19

#	ARTICLE	IF	CITATIONS
271	Alteration of matrix metalloproteinase-3 O-glycan structure as a biomarker for disease activity of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 112.	3.5	19
272	IgG4-related disease involving vital organs diagnosed with lip biopsy. <i>Medicine (United States)</i> , 2016, 95, e3970.	1.0	19
273	Determinants of Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity in patients with rheumatoid arthritis: A <i>post hoc</i> analysis of overall and Japanese results from phase 3 clinical trials. <i>Modern Rheumatology</i> , 2018, 28, 960-967.	1.8	19
274	Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. <i>Rheumatology</i> , 2019, 58, 1034-1039.	1.9	19
275	Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 46.	3.5	19
276	Expression of Gab1 Lacking the Pleckstrin Homology Domain Is Associated with Neoplastic Progression. <i>Molecular and Cellular Biology</i> , 2001, 21, 6895-6905.	2.3	18
277	ALTERED EXPRESSION OF THE T CELL RECEPTOR-CD3 COMPLEX IN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>International Reviews of Immunology</i> , 2004, 23, 273-291.	3.3	18
278	DNA Microarray Gene Expression Profile of T Cells with the Splice Variants of TCR $\alpha$ mRNA Observed in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2006, 176, 949-956.	0.8	18
279	Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2008, 18, 442-446.	1.8	18
280	Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan. <i>Modern Rheumatology</i> , 2018, 28, 48-57.	1.8	18
281	Longitudinal immune cell monitoring identified CD14 <sup>++</sup> CD16 <sup>+</sup> intermediate monocyte as a marker of relapse in patients with ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2020, 22, 145.	3.5	18
282	Elevated expression of BAFF receptor, BR3, on monocytes correlates with B cell activation and clinical features of patients with primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2020, 22, 157.	3.5	18
283	Antigen-driven selection of antibodies against SSA, SSB and the centromere $\alpha$ -complex, including a novel antigen, MIS12 complex, in human salivary glands. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 150-158.	0.9	18
284	Reactivity of Monoclonal Antibodies to Species-Specific Antigens of <i>Entamoeba histolytica</i> . <i>Journal of Protozoology</i> , 1991, 38, 329-334.	0.8	17
285	Interleukin-4 and IgE in Seasonal Allergic Conjunctivitis. <i>Ophthalmologica</i> , 1996, 210, 325-328.	1.9	17
286	ADAMTS5 Is a Biomarker for Prediction of Response to Infliximab in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1454-1460.	2.0	17
287	Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis. <i>Rheumatology International</i> , 2012, 32, 1511-1519.	3.0	17
288	CD247 variants and single-nucleotide polymorphisms observed in systemic lupus erythematosus patients. <i>Rheumatology</i> , 2013, 52, 1551-1555.	1.9	17

#	ARTICLE	IF	CITATIONS
289	Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2829-2834.	2.2	17
290	Importance of Obtaining Remission for Work Productivity and Activity of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1112-1117.	2.0	17
291	Pre-treatment interleukin-6 levels strongly affect bone erosion progression and repair detected by magnetic resonance imaging in rheumatoid arthritis patients. <i>Rheumatology</i> , 2017, 56, 1089-1094.	1.9	17
292	Clinical and Immunological Features of Anti-centromere Antibody-Positive Primary Sjögren's Syndrome. <i>Rheumatology and Therapy</i> , 2018, 5, 499-505.	2.3	17
293	Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2019, 59, 145-155.	0.8	17
294	Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. <i>Modern Rheumatology</i> , 2019, 29, 747-755.	1.8	17
295	Efficacy and Safety of E6011, an Anti-IL-6 Receptor Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 587-595.	5.6	17
296	Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). <i>Arthritis Research and Therapy</i> , 2021, 23, 9.	3.5	17
297	Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. <i>Modern Rheumatology</i> , 2013, 23, 226-235.	1.8	17
298	Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Tj ETQq0 02rgBT /Overlock 10		
299	AMEBIASIS IN INSTITUTIONS FOR THE MENTALLY RETARDED IN KANAGAWA PREFECTURE, JAPAN. <i>Japanese Journal of Medical Science and Biology</i> , 1990, 43, 123-131.	0.4	17
300	"Not at target": prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, 70.	3.5	17
301	Suppressor t cell function in patients with rheumatoid arthritis complicated by vasculitis. <i>Arthritis and Rheumatism</i> , 1984, 27, 752-759.	6.7	16
302	Tyrosine Phosphorylated Proteins in Synovial Cells of Rheumatoid Arthritis. <i>International Reviews of Immunology</i> , 1998, 17, 365-382.	3.3	16
303	Rheumatoid Arthritis and Tumor Necrosis Factor $\hat{\pm}$ . <i>Autoimmunity</i> , 2001, 34, 291-303.	2.6	16
304	Diagnostic significance of serum soluble transferrin receptors in various anemic diseases: the first multi-institutional joint study in Japan. <i>Haematologia</i> , 2002, 32, 225-238.	0.3	16
305	Successful Non-Surgical Treatment of Brain Abscess and Necrotizing Fasciitis Caused by <i>Bacillus cereus</i> . <i>Internal Medicine</i> , 2002, 41, 671-673.	0.7	16
306	Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients. <i>Modern Rheumatology</i> , 2004, 14, 442-446.	1.8	16

#	ARTICLE	IF	CITATIONS
307	Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. <i>Modern Rheumatology</i> , 2006, 16, 381-388.	1.8	16
308	Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: A single-center retrospective cohort study (KEIO-TCZ study) at week 52. <i>Modern Rheumatology</i> , 2015, 25, 31-37.	1.8	16
309	Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials. <i>Modern Rheumatology</i> , 2015, 25, 173-186.	1.8	16
310	Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis. <i>Cytokine</i> , 2015, 75, 222-227.	3.2	16
311	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). <i>Modern Rheumatology</i> , 2018, 28, 642-648.	1.8	16
312	Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. <i>Rheumatology</i> , 2019, 58, 997-1005.	1.9	16
313	Lymphadenopathy in IgG4-related disease: a phenotype of severe activity and poor prognosis, with eotaxin-3 as a new biomarker. <i>Rheumatology</i> , 2021, 60, 967-975.	1.9	16
314	Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan. <i>Rheumatology and Therapy</i> , 2021, 8, 425-442.	2.3	16
315	Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. <i>Modern Rheumatology</i> , 2014, 24, 399-404.	1.8	15
316	Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. <i>Modern Rheumatology</i> , 2014, 24, 885-891.	1.8	15
317	Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orenzia <sup>®</sup> as Biological Intensive Treatment for RA (ORBIT) study. <i>Modern Rheumatology</i> , 2014, 24, 754-762.	1.8	15
318	Acute Kidney Injury due to Renal Sarcoidosis during Etanercept Therapy: A Case Report and Literature Review. <i>Internal Medicine</i> , 2015, 54, 1131-1134.	0.7	15
319	Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis. <i>International Immunology</i> , 2017, 29, 511-517.	4.0	15
320	IL-6, IL-17 and Stat3 are required for auto-inflammatory syndrome development in mouse. <i>Scientific Reports</i> , 2018, 8, 15783.	3.3	15
321	Ten-year observation of patients with primary Sjögren's syndrome: Initial presenting characteristics and the associated outcomes. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 929-933.	1.9	15
322	Long-term Safety and Effectiveness of Tacrolimus in Patients With Lupus Nephritis: 5-year Interim Postmarketing Surveillance Study in Japan (TRUST). <i>Journal of Rheumatology</i> , 2021, 48, 74-81.	2.0	15
323	The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. <i>Drug Safety</i> , 2021, 44, 711-722.	3.2	15
324	Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients. <i>Modern Rheumatology</i> , 2013, 23, 219-225.	1.8	15

#	ARTICLE	IF	CITATIONS
325	In vitro anti-DNA antibody synthesis by peripheral blood lymphocytes in patients with systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1981, 21, 237-246.	2.0	14
326	What is the future of CCR5 antagonists in rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2012, 14, 114.	3.5	14
327	Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud's phenomenon. <i>Rheumatology</i> , 2015, 54, 349-358.	1.9	14
328	Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study. <i>Modern Rheumatology</i> , 2018, 28, 611-620.	1.8	14
329	Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study. <i>Clinical Rheumatology</i> , 2018, 37, 765-771.	2.2	14
330	Significant association between clinical characteristics and immuno-phenotypes in patients with ANCA-associated vasculitis. <i>Rheumatology</i> , 2020, 59, 545-553.	1.9	14
331	Significant association between joint ultrasonographic parameters and synovial inflammatory factors in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 14.	3.5	14
332	Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. <i>Modern Rheumatology</i> , 2021, 31, 34-41.	1.8	14
333	Autoimmune Epithelitis and Chronic Inflammation in Sjögren's Syndrome-Related Dry Eye Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11820.	4.1	14
334	Spontaneous production of antibodies to deoxyribonucleic acids in patients with systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1985, 35, 47-56.	2.0	13
335	Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. <i>BMC Gastroenterology</i> , 2013, 13, 54.	2.0	13
336	Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan. <i>Modern Rheumatology</i> , 2015, 25, 43-49.	1.8	13
337	Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial. <i>Modern Rheumatology</i> , 2016, 26, 481-490.	1.8	13
338	Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients. <i>Arthritis Research and Therapy</i> , 2018, 20, 42.	3.5	13
339	Adolescent PR3-ANCA-positive hypertrophic pachymeningitis. <i>Medicine (United States)</i> , 2018, 97, e0521.	1.0	13
340	Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 94-102.	0.9	13
341	Development of an intravital imaging system for the synovial tissue reveals the dynamics of CTLA-4 Ig in vivo. <i>Scientific Reports</i> , 2020, 10, 13480.	3.3	13
342	Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review. <i>Modern Rheumatology</i> , 2022, 32, 231-237.	1.8	13

#	ARTICLE	IF	CITATIONS
343	Lacrimation and Salivation are Not Related to Lymphocytic Infiltration in Lacrimal and Salivary Glands in MRL lpr/lpr Mice. <i>Advances in Experimental Medicine and Biology</i> , 1998, 438, 941-948.	1.6	13
344	Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2008, 18, 442-446.	1.8	13
345	Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. <i>Modern Rheumatology</i> , 2013, 23, 1211-20.	1.8	13
346	Subclinical labial salivary gland involvement in IgG4-related disease affected with vital organs. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 949-50.	0.8	13
347	Anti-TNF Biological Agents in Rheumatoid Arthritis and Other Inflammatory Diseases. <i>Allergy International</i> , 2005, 54, 191-202.	3.3	12
348	Safety and Effectiveness of 6 Monthsâ€™ Etanercept Monotherapy and Combination Therapy in Japanese Patients with Rheumatoid Arthritis: Effect of Concomitant Disease-modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2013, 40, 1658-1668.	2.0	12
349	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. <i>Modern Rheumatology</i> , 2014, 24, 725-733.	1.8	12
350	Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs. <i>Modern Rheumatology</i> , 2014, 24, 744-753.	1.8	12
351	Resolution of elevated circulating regulatory T cells by corticosteroids in patients with IgG4-related dacryoadenitis and sialoadenitis. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 430-432.	1.9	12
352	Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. <i>Arthritis Research and Therapy</i> , 2017, 19, 56.	3.5	12
353	Interleukin-6 in idiopathic multicentric Castlemanâ€™s disease after long-term tocilizumab. <i>Annals of Hematology</i> , 2017, 96, 2117-2119.	1.8	12
354	Polymyositis with elevated serum IgG4 levels and abundant IgG4+ plasma cell infiltration. <i>Medicine (United States)</i> , 2017, 96, e8710.	1.0	12
355	Effectiveness of tacrolimus on IgG4-related disease. <i>Modern Rheumatology</i> , 2019, 29, 892-894.	1.8	12
356	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1255-1257.	1.9	12
357	Is type 2 diabetes mellitus an inverse risk factor for the development of rheumatoid arthritis?. <i>Journal of Human Genetics</i> , 2021, 66, 219-223.	2.3	12
358	Immunoglobulin G4-related disease and idiopathic multicentric Castlemanâ€™s disease: confusable immune-mediated disorders. <i>Rheumatology</i> , 2022, 61, 490-501.	1.9	12
359	Salivary gland involvement in ANCA-associated vasculitis. <i>Autoimmunity Reviews</i> , 2021, 20, 102940.	5.8	12
360	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDsâ€™ a multicenter, double-blind, parallel-group trial. <i>Modern Rheumatology</i> , 2011, 21, 458-468.	1.8	12

#	ARTICLE	IF	CITATIONS
361	Measurement of interleukin-4 and histamine in superficial cells of conjunctiva in patients with allergic conjunctivitis. <i>Current Eye Research</i> , 1996, 15, 209-213.	1.5	11
362	Past Japanese successes show the way to accomplish future goals. <i>Trends in Parasitology</i> , 2007, 23, 260-267.	3.3	11
363	Microscopic polyangitis complicating double carcinoma of the stomach and duodenum: improvement after the resection of these carcinomas. <i>Rheumatology International</i> , 2011, 31, 105-108.	3.0	11
364	Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. <i>Modern Rheumatology</i> , 2013, 23, 97-103.	1.8	11
365	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. <i>Modern Rheumatology</i> , 2014, 24, 734-743.	1.8	11
366	Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. <i>Modern Rheumatology</i> , 2015, 25, 11-20.	1.8	11
367	Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders. <i>Modern Rheumatology</i> , 2015, 25, 665-671.	1.8	11
368	Abatacept in combination with methotrexate in Japanese biologic-naïve patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. <i>RMD Open</i> , 2018, 4, e000813.	3.8	11
369	Synergistic effect of IgG4 antibody and CTLs causes tissue inflammation in IgG4-related disease. <i>International Immunology</i> , 2020, 32, 163-174.	4.0	11
370	Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-218710.	0.9	11
371	Tocilizumab monotherapy uncovered the role of the CCL22/17â€œCCR4<sup>+</sup> Treg axis during remission of crescentic glomerulonephritis. <i>Clinical and Translational Immunology</i> , 2020, 9, e1203.	3.8	11
372	CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 671-674.	0.9	11
373	Distinct Expression of Coinhibitory Molecules on Alveolar T Cells in Patients With Rheumatoid Arthritisâ€œAssociated and Idiopathic Inflammatory Myopathyâ€œAssociated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 576-586.	5.6	11
374	A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. <i>Modern Rheumatology</i> , 2021, 31, 783-789.	1.8	11
375	Steroid-Sparing Effect of Tocilizumab and Methotrexate in Patients with Polymyalgia Rheumatica: A Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2948.	2.4	11
376	An update on the pathogenic role of IL-6 in rheumatic diseases. <i>Cytokine</i> , 2021, 146, 155645.	3.2	11
377	Successful treatment of embryo implantation failure in patients with the SjÃ¶gren syndrome with low-dose prednisolone. <i>Fertility and Sterility</i> , 2001, 75, 640-641.	1.0	10
378	TCRÎ¶ mRNA splice variant forms observed in the peripheral blood T cells from systemic lupus erythematosus patients. <i>Seminars in Immunopathology</i> , 2006, 28, 185-193.	4.0	10

#	ARTICLE	IF	CITATIONS
379	Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study. <i>Rheumatology International</i> , 2012, 32, 1617-1624.	3.0	10
380	Early achievement of complete renal response predicts good long-term renal outcome and low systemic damage in newly diagnosed lupus nephritis class III or IV. <i>Modern Rheumatology</i> , 2015, 25, 714-718.	1.8	10
381	Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. <i>RMD Open</i> , 2017, 3, e000465.	3.8	10
382	Treatment of rheumatoid arthritis with biological agents as a typical and common immune-mediated inflammatory disease. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2017, 93, 600-608.	3.8	10
383	Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study. <i>RMD Open</i> , 2018, 4, e000731.	3.8	10
384	Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data. <i>Modern Rheumatology</i> , 2019, 29, 756-766.	1.8	10
385	Characteristics and prognosis of ANCA-positive retroperitoneal fibrosis: A systematic literature review. <i>Autoimmunity Reviews</i> , 2020, 19, 102642.	5.8	10
386	ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2020, 22, 252.	3.5	10
387	Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. <i>Journal of Rheumatology</i> , 2021, 48, 1663-1671.	2.0	10
388	Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. <i>Modern Rheumatology</i> , 2006, 16, 381-388.	1.8	10
389	Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010, 20, 337-342.	1.8	10
390	Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. <i>Modern Rheumatology</i> , 2013, 23, 97-103.	1.8	10
391	Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). <i>Modern Rheumatology</i> , 2022, 32, 263-272.	1.8	10
392	Normalisation of physical function by infliximab in patients with RA: factors associated with normal physical function. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 365-72.	0.8	10
393	Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 157-164.	0.8	10
394	Systemic lupus erythematosus with necrotizing vasculitis and upregulated expression of VLA-4 antigen. <i>Clinical Rheumatology</i> , 1995, 14, 370-374.	2.2	9
395	Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010, 20, 337-342.	1.8	9
396	American College of Rheumatology/European League Against Rheumatism Remission Criteria for Rheumatoid Arthritis Maintain Reliable Performance When Evaluated in 44 Joints. <i>Journal of Rheumatology</i> , 2013, 40, 1254-1258.	2.0	9

#	ARTICLE	IF	CITATIONS
397	Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial. <i>Modern Rheumatology</i> , 2014, 24, 561-566.	1.8	9
398	Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016, 26, 473-480.	1.8	9
399	Comparison of the Clinical Characteristics of Pneumocystis Pneumonia between Patients with Rheumatoid Arthritis Being Treated with Biologics and Those Being Treated without Biologics. <i>BioMed Research International</i> , 2017, 2017, 1-6.	1.9	9
400	Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results. <i>Modern Rheumatology</i> , 2018, 28, 85-94.	1.8	9
401	Increased proportion of a CD38 <sup>high</sup> IgD <sup>+</sup> B cell subset in peripheral blood is associated with clinical and immunological features in patients with primary Sjögren's syndrome. <i>Clinical Immunology</i> , 2018, 187, 85-91.	3.2	9
402	Histopathological classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a nationwide Japanese prospective 2-year follow-up cohort study. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 387-394.	1.6	9
403	Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review. <i>Annals of Hematology</i> , 2020, 99, 2463-2475.	1.8	9
404	Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e120-e120.	0.9	9
405	Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). <i>RMD Open</i> , 2021, 7, e001465.	3.8	9
406	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. <i>Rheumatology</i> , 2021, 60, 5185-5193.	1.9	9
407	High serum IgA and activated Th17 and Treg predict the efficacy of abatacept in patients with early, seropositive rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 3615-3626.	2.2	9
408	Identification of neutrophil $\alpha$ 2-integrin LFA-1 as a potential mechanistic biomarker in ANCA-associated vasculitis via microarray and validation analyses. <i>Arthritis Research and Therapy</i> , 2021, 23, 136.	3.5	9
409	Efficacy and safety of bucillamine, a d-penicillamine analogue, in patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2006, 16, 85-91.	1.8	9
410	T-cell receptor $\alpha$ mRNA with an alternatively spliced 3' untranslated region is generated predominantly in the peripheral blood T cells of systemic lupus erythematosus patients. <i>Modern Rheumatology</i> , 2002, 12, 167-173.	1.8	9
411	Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1273-1280.	0.9	9
412	Mitogenic Responses to Lipopolysaccharide by B Lymphocytes from Patients with Systemic Lupus Erythematosus. <i>Scandinavian Journal of Immunology</i> , 1982, 15, 475-482.	2.7	8
413	Respiratory syncytial virus-induced interleukin-4 production by human conjunctival epithelial cells contributes to allergy: preliminary study. <i>Current Eye Research</i> , 1998, 17, 656-662.	1.5	8
414	Amebiasis in Acquired Immunodeficiency Syndrome. <i>Internal Medicine</i> , 2001, 40, 563-564.	0.7	8

#	ARTICLE	IF	CITATIONS
415	Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction. <i>Modern Rheumatology</i> , 2009, 19, 166-172.	1.8	8
416	Reduced Expression of TCR Zeta Is Involved in the Abnormal Production of Cytokines by Peripheral T Cells of Patients with Systemic Lupus Erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-6.	3.0	8
417	Distinct arthropathies of the hands in patients with anti-aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients. <i>Rheumatology</i> , 2014, 53, 1120-1124.	1.9	8
418	Anti-signal recognition particle antibody in patients without inflammatory myopathy: a survey of 6180 patients with connective tissue diseases. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 36-40.	1.1	8
419	A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 231.	3.5	8
420	Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2019, 60, 2508-2515.	1.3	8
421	Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. <i>RMD Open</i> , 2020, 6, e001249.	3.8	8
422	Interleukin-1 pathway in active large vessel vasculitis patients with a poor prognosis: a longitudinal transcriptome analysis. <i>Clinical and Translational Immunology</i> , 2021, 10, e1307.	3.8	8
423	Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: Interim analysis of a multicentre cohort study. <i>Modern Rheumatology</i> , 2023, 33, 367-372.	1.8	8
424	CCA [N-(2-carboxyphenyl)-4-Chloroanthranilic acid disodium salt], a newly developed immunomodulating drug, suppresses T-cell activation by acting on macrophages. <i>Inflammation</i> , 1989, 13, 125-135.	3.8	7
425	Parvovirus B 19 Infection in Adults. <i>Internal Medicine</i> , 2002, 41, 247-248.	0.7	7
426	De novo CD5+ diffuse large B cell lymphoma with basophilia in the peripheral blood: Successful treatment with autologous peripheral blood stem cell transplantation. <i>American Journal of Hematology</i> , 2007, 82, 162-167.	4.1	7
427	Differences in protein profiles of the isolates of <i>Entamoeba histolytica</i> and <i>E. dispar</i> by surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS) ProteinChip assays. <i>Parasitology Research</i> , 2007, 102, 103-110.	1.6	7
428	Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study. <i>Modern Rheumatology</i> , 2013, 23, 634-645.	1.8	7
429	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. <i>Modern Rheumatology</i> , 2013, 23, 1045-1052.	1.8	7
430	Crohn's Disease in which the Patient Developed Aortitis during Treatment with Adalimumab. <i>Internal Medicine</i> , 2015, 54, 1725-1732.	0.7	7
431	Prediction of Clinical Response After 1 Year of Infliximab Therapy in Rheumatoid Arthritis Based on Disease Activity at 3 Months: Posthoc Analysis of the RISING Study. <i>Journal of Rheumatology</i> , 2015, 42, 599-607.	2.0	7
432	Bendamustine increases interleukin-10 secretion from B cells via p38 MAP kinase activation. <i>International Immunopharmacology</i> , 2016, 39, 273-279.	3.8	7

#	ARTICLE	IF	CITATIONS
433	Poor renal outcomes in patients with anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis and normal renal function at diagnosis. <i>Clinical Rheumatology</i> , 2016, 35, 495-500.	2.2	7
434	Survey on attitudes regarding EULAR recommendations for the role of nurses involved in medical care of patients with chronic inflammatory arthritis in Japan. <i>Modern Rheumatology</i> , 2017, 27, 886-893.	1.8	7
435	Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 553-557.	2.0	7
436	Proteinuria selectivity index as a prognostic biomarker in lupus nephritis. <i>Lupus</i> , 2017, 26, 656-660.	1.6	7
437	Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study. <i>Modern Rheumatology</i> , 2017, 27, 284-291.	1.8	7
438	Effectiveness and safety of initiating adalimumab plus 12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan. <i>Modern Rheumatology</i> , 2019, 29, 572-580.	1.8	7
439	Body mass index associates with disease relapse in patients with giant cell arteritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1782-1786.	1.9	7
440	Lupus aortitis: A fatal, inflammatory cardiovascular complication in systemic lupus erythematosus. <i>Lupus</i> , 2020, 29, 1652-1654.	1.6	7
441	Distinct features between HLA-DR+ and HLA-DR~ PD-1hi CXCR5+ T peripheral helper cells in seropositive rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 451-460.	1.9	7
442	Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 221.	3.5	7
443	Studies on Current Trend of Imported Malaria in Japan.. <i>Tropical Medicine and Health</i> , 1998, 26, 151-156.	0.1	7
444	Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics. <i>Modern Rheumatology</i> , 2021, , .	1.8	7
445	Long-term safety and effectiveness of mycophenolate mofetil in adults with lupus nephritis: a real-world study in Japan. <i>Modern Rheumatology</i> , 2022, 32, 746-754.	1.8	7
446	No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. <i>Modern Rheumatology</i> , 2013, 23, 945-952.	1.8	7
447	Effect of genetic polymorphisms of azathioprine-metabolizing enzymes on response to rheumatoid arthritis treatment. <i>Die Pharmazie</i> , 2017, 72, 22-28.	0.5	7
448	DNA polymerase activity in encysting <i>Entamoeba invadens</i> . <i>Parasitology Research</i> , 1999, 85, 604-606.	1.6	6
449	Therapeutic Targets of Misguided T Cells in Systemic Lupus Erythematosus. <i>Inflammation and Allergy: Drug Targets</i> , 2005, 4, 295-298.	3.1	6
450	Down-regulation of Fas-ligand mRNA in Sjögren's syndrome patients with enlarged exocrine glands. <i>Autoimmunity</i> , 2007, 40, 497-502.	2.6	6

#	ARTICLE	IF	CITATIONS
451	Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases. <i>Drug Target Insights</i> , 2007, 2, 117739280700200.	1.4	6
452	Notable Difference between the Development of Vertebral Fracture and Osteonecrosis of the Femoral Head in Patients Treated with High-dose Glucocorticoids for Systemic Rheumatic Diseases. <i>Internal Medicine</i> , 2009, 48, 1931-1938.	0.7	6
453	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. <i>Modern Rheumatology</i> , 2012, 22, 186-194.	1.8	6
454	A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 310-312.	0.9	6
455	A unique case of polymyositis with anti-signal recognition particle antibody complicated by subacute interstitial lung disease and subluxing arthropathy, resembling anti-synthetase syndrome. <i>Modern Rheumatology</i> , 2016, 26, 979-980.	1.8	6
456	Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study. <i>Modern Rheumatology</i> , 2016, 26, 323-330.	1.8	6
457	Polychondritis presenting with oculomotor and abducens nerve palsies as the initial manifestation. <i>Modern Rheumatology</i> , 2016, 26, 790-793.	1.8	6
458	Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study. <i>Biological and Pharmaceutical Bulletin</i> , 2018, 41, 1414-1422.	1.4	6
459	Impact of subclinical synovitis in ankles and feet detected by ultrasonography in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 62-67.	1.9	6
460	Does microbiome contribute to HLA-B52-positive Takayasu arteritis?. <i>Modern Rheumatology</i> , 2020, 30, 213-217.	1.8	6
461	The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method. <i>Modern Rheumatology</i> , 2020, 30, 525-531.	1.8	6
462	Biomarkers for disease flare in patients with adult-onset Still's disease undergoing treatment with tocilizumab. <i>Rheumatology</i> , 2020, 59, 440-442.	1.9	6
463	A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. <i>Modern Rheumatology</i> , 2021, 31, 543-555.	1.8	6
464	Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. <i>Modern Rheumatology</i> , 2021, 31, 534-542.	1.8	6
465	Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). <i>Modern Rheumatology</i> , 2022, 32, 59-67.	1.8	6
466	Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1491-1493.	0.9	6
467	Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still's disease. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 79-85.	3.1	6
468	Molecular remission at T cell level in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2021, 11, 16691.	3.3	6

#	ARTICLE	IF	CITATIONS
469	Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study. <i>Modern Rheumatology</i> , 2013, 23, 634-645.	1.8	6
470	Should we reconsider the definition of elderly-onset rheumatoid arthritis in an ageing society?. <i>Modern Rheumatology</i> , 2022, 32, 323-329.	1.8	6
471	Defects of Autologous Mixed Lymphocyte Reaction-Activated Immunoregulatory T Cells in Patients with Systemic Lupus Erythematosus. <i>Scandinavian Journal of Immunology</i> , 1987, 26, 363-369.	2.7	5
472	Amplification of suppressor inducer pathway with monoclonal antibody, anti-2H4, identifying a novel epitope of the common leukocyte antigen/T200 antigen. <i>Cellular Immunology</i> , 1989, 118, 68-84.	3.0	5
473	Integrin VLA-5 Negative Primary Plasma Cell Leukemia.. <i>Internal Medicine</i> , 1993, 32, 565-568.	0.7	5
474	The other side of TNF-targeted therapy of patients with rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2001, 3, 1-2.	4.7	5
475	Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. <i>Modern Rheumatology</i> , 2013, , 1.	1.8	5
476	Intriguing Findings of the Muscle on Magnetic Resonance Imaging in Polyarteritis Nodosa. <i>Internal Medicine</i> , 2016, 55, 3197-3200.	0.7	5
477	Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. <i>Rheumatology and Therapy</i> , 2016, 3, 155-166.	2.3	5
478	Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan. <i>Modern Rheumatology</i> , 2017, 27, 787-794.	1.8	5
479	Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study. <i>Modern Rheumatology</i> , 2018, 28, 39-47.	1.8	5
480	Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120. <i>Modern Rheumatology</i> , 2018, 28, 770-779.	1.8	5
481	THU0078â€¦SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. , 2019, , .		5
482	Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients. <i>Modern Rheumatology</i> , 2004, 14, 442-446.	1.8	5
483	Functional Differences of Anti-T-Cell Antibody in Patients with Systemic Lupus Erythematosus and Ulcerative Colitis. <i>Scandinavian Journal of Immunology</i> , 1983, 18, 521-530.	2.7	4
484	DNA-daunorubicin complexes specifically suppress in vitro spontaneous anti-DNA antibody production in lymphocytes of patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1986, 29, 1216-1222.	6.7	4
485	Suppression of in Vitro Production of Anti-U1-Ribonucleoprotein Antibody by Monoclonal Anti-Idiotypic Antibody to Anti-U1-Ribonucleoprotein Antibody. <i>Scandinavian Journal of Immunology</i> , 1988, 28, 687-696.	2.7	4
486	The Presence of Anti-Protein A Antibodies in Patients with Rheumatoid Arthritis. <i>Scandinavian Journal of Immunology</i> , 1991, 33, 585-592.	2.7	4

#	ARTICLE	IF	CITATIONS
487	Nosocomial Pneumonia Likely Caused by <i>Stenotrophomonas Maltophilia</i> in Two Patients with Polymyositis.. <i>Internal Medicine</i> , 1999, 38, 910-916.	0.7	4
488	Role of Adhesion Molecules in Vasculitis Syndrome.. <i>Internal Medicine</i> , 2002, 41, 41-44.	0.7	4
489	Severe degenerative change of multiple organs mediated by chronic active Epstein-Barr virus infection with infected T-cell expansion. <i>International Journal of Hematology</i> , 2008, 87, 520-526.	1.6	4
490	Conservative sequences in 3'UTR of TCR $\beta$ mRNA regulate TCR $\beta$ in SLE T cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 367, 311-317.	2.1	4
491	Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis:post hoc time-course analysis of an all-case PMS in Japan. <i>Modern Rheumatology</i> , 2015, 25, 495-502.	1.8	4
492	Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. <i>Contemporary Clinical Trials Communications</i> , 2017, 8, 49-54.	1.1	4
493	Considering new lessons about the use of IL-6 inhibitors in arthritis. <i>Considerations in Medicine</i> , 2018, 2, 7-11.	0.0	4
494	Interleukin-4 as an emerging therapeutic target for IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-216961.	0.9	4
495	Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 316-324.	1.9	4
496	Refractory IgG4-related Pleural Disease with Chylothorax: A Case Report and Literature Review. <i>Internal Medicine</i> , 2021, 60, 2135-2143.	0.7	4
497	Proton Pump Inhibitor and Tacrolimus Uses are Associated With Hypomagnesemia in Connective Tissue Disease: a Potential Link With Renal Dysfunction and Recurrent Infection. <i>Frontiers in Pharmacology</i> , 2021, 12, 616719.	3.5	4
498	A case of eosinophilic granulomatosis with polyangiitis after prolonged intervals of an anti-interleukin-6 receptor antibody for rheumatoid arthritis. <i>Modern Rheumatology Case Reports</i> , 2022, 6, 83-86.	0.7	4
499	Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction. <i>Modern Rheumatology</i> , 2009, 19, 166-172.	1.8	4
500	Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases. <i>Drug Target Insights</i> , 2007, 2, 239-47.	1.4	4
501	Rheumatoid arthritis with nontuberculous mycobacterial pulmonary disease: a retrospective, single-centre cohort study. <i>Modern Rheumatology</i> , 2022, 32, 534-540.	1.8	4
502	Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 3777-3791.	1.9	4
503	Respiratory syncytial virus-induced interleukin-4 production by human conjunctival epithelial cells contributes to allergy: preliminary study. <i>Current Eye Research</i> , 1998, 17, 656-662.	1.5	4
504	Clinical Manifestations and Prognosis of Wegener's Granulomatosis. <i>Internal Medicine</i> , 1995, 34, 705-706.	0.7	3

#	ARTICLE	IF	CITATIONS
505	Clinical significance of elevated serum levels of matrix metalloproteinase-3 and C-reactive protein in patients with rheumatoid arthritis. <i>APLAR Journal of Rheumatology</i> , 2007, 10, 295-299.	0.2	3
506	Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary <i>Mycobacterium avium</i> complex lesion: a case report. <i>BMC Pulmonary Medicine</i> , 2015, 15, 126.	2.0	3
507	An unusual association between focal segmental sclerosis and lupus nephritis: a distinct concept from lupus podocytopathy?. <i>CEN Case Reports</i> , 2015, 4, 70-75.	0.9	3
508	Enlargement of thymoma triggers overlapping autoimmune diseases. <i>Autoimmunity Reviews</i> , 2016, 15, 1200-1201.	5.8	3
509	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). <i>Rheumatology and Therapy</i> , 2016, 3, 129-141.	2.3	3
510	Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2017, 27, 778-781.	1.8	3
511	Persistent fever and destructive arthritis caused by dialysis-related amyloidosis. <i>Medicine (United States)</i> , 2017, 96, 1074-1078.	1.0	3
512	Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study. <i>Modern Rheumatology</i> , 2018, 28, 941-949.	1.8	3
513	Targeting IL-6: A review of data. <i>Considerations in Medicine</i> , 2018, 2, 12-18.	0.0	3
514	Subtypes in eosinophilic granulomatosis with polyangiitis classified according to rheumatoid factor. <i>Clinical Rheumatology</i> , 2019, 38, 3493-3499.	2.2	3
515	Initial presentation determines clinical entity in patients with anti-centromere antibody positivity. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 103-107.	1.9	3
516	Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T). <i>Modern Rheumatology</i> , 2019, 29, 306-313.	1.8	3
517	Safety and tolerability of ultrasound-guided synovial needle biopsy in Japanese arthritis patients. <i>Modern Rheumatology</i> , 2021, 31, 960-965.	1.8	3
518	Value of labial salivary gland histopathology for diagnosis of Sjögren's syndrome in patients with anti-centromere antibody positivity. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1024-1029.	1.9	3
519	Etiology of IgG4-Related Pulmonary Hypertension. <i>Cardiology</i> , 2020, 145, 263-266.	1.4	3
520	Response to: "Some concerns from Turkey" by Bilgin et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e16-e16.	0.9	3
521	Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. <i>Arthritis and Rheumatism</i> , 2001, 44, 550-560.	6.7	3
522	Impact of TNF inhibitors on rheumatoid arthritis. <i>Inflammation and Regeneration</i> , 2006, 26, 148-159.	3.7	3

#	ARTICLE	IF	CITATIONS
523	Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). <i>Modern Rheumatology</i> , 2022, 32, 273-283.	1.8	3
524	Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. <i>Rheumatology</i> , 2022, 61, 4273-4285.	1.9	3
525	The Efficacy and Safety of Anifrolumab in Japanese Patients With Systemic Lupus Erythematosus: TULIP-2 Subanalysis. <i>Modern Rheumatology</i> , 2022, , .	1.8	3
526	<i>Post hoc</i> analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). <i>Modern Rheumatology</i> , 2022, , .	1.8	3
527	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). <i>Modern Rheumatology</i> , 2007, 17, 178-178.	1.8	3
528	Cellular regulation of anti-nRNP antibody synthesis is different from that of anti-DNA antibody synthesis in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 1988, 8, 177-183.	3.0	2
529	<i>Internal Medicine</i> , 1999, 38, 169-169.	0.7	2
530	Molecular abnormalities of T-cells in systemic lupus erythematosus. <i>APLAR Journal of Rheumatology</i> , 2006, 9, 365-371.	0.2	2
531	Treatment of Inflammatory Immunologic Disease 3. Anti-TNF Therapy in Rheumatoid Arthritis. <i>Internal Medicine</i> , 2007, 46, 1311-1312.	0.7	2
532	1. Rheumatoid Arthritis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2010, 99, 2392-2400.	0.0	2
533	Osteolytic change of distal interphalangeal joints and sacroiliac joints in subluxing arthropathy associated with anti-Jo-1 antibody. <i>Joint Bone Spine</i> , 2013, 80, 544-545.	1.6	2
534	4. Progress in Rheumatoid Arthritis Therapy and Future Perspective. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2015, 104, 1773-1782.	0.0	2
535	Response to: â€ˆDenosumab, cortical bone and bone erosion in rheumatoid arthritisâ€™™ by Rossiniet al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e71-e71.	0.9	2
536	Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients. <i>Modern Rheumatology</i> , 2016, 26, 676-680.	1.8	2
537	Pulmonary Cryptococcosis Developed from a Nodule after Treatment with Infliximab for Arthritis Associated with Ulcerative Colitis. <i>Annals of the American Thoracic Society</i> , 2017, 14, 603-605.	3.2	2
538	Successful rituximab treatment of granulomatosis with polyangiitis with cranial neuropathies. <i>Inflammation and Regeneration</i> , 2018, 38, 20.	3.7	2
539	Pulmonary Vein Vasculitis Presenting as Multiple Pulmonary Nodules in a Patient with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019, 46, 323-324.	2.0	2
540	Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab. <i>Inflammation and Regeneration</i> , 2019, 39, 5.	3.7	2

#	ARTICLE	IF	CITATIONS
541	IgG4-Related Disease: A Growing Appreciation of Follicular Helper T Cell Expansion. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00076.	2.5	2
542	Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A <i>post hoc</i> analysis of the SURPRISE study. <i>Modern Rheumatology</i> , 2020, 30, 442-449.	1.8	2
543	Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-naïve patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2020, 30, 259-268.	1.8	2
544	A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate. <i>Modern Rheumatology</i> , 2021, 31, 53-60.	1.8	2
545	Characteristics and prognosis of IgG4-related skin disease: A case report and systematic literature review. <i>Autoimmunity Reviews</i> , 2021, 20, 102805.	5.8	2
546	Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. <i>Arthritis Research and Therapy</i> , 2021, 23, 220.	3.5	2
547	Sero epidemiological Study on Human Toxocariasis in the Rural Sector Around Recife, Northeast Brazil. <i>Tropical Medicine and Health</i> , 1993, 21, 255-258.	0.1	2
548	Abnormalities of B cell stimulatory factors (BSF) produced by T cells and B cell response to BSF from patients with systemic lupus erythematosus (SLE). <i>Japanese Journal of Clinical Immunology</i> , 1984, 7, 208-215.	0.0	2
549	A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years. <i>Modern Rheumatology</i> , 2022, 32, 708-717.	1.8	2
550	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. <i>Modern Rheumatology</i> , 2012, 22, 186-194.	1.8	2
551	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. <i>Modern Rheumatology</i> , 2013, 23, 1045-52.	1.8	2
552	Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: <i>post hoc</i> analysis of a randomized, placebo-controlled, phase 4 study. <i>Modern Rheumatology</i> , 2022, 32, 500-507.	1.8	2
553	Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren's syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's Syndrome) <i>Tj ETQq1 10.784314 rgBT /C</i>	1.8	2
554	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years. <i>Modern Rheumatology</i> , 2023, 33, 64-72.	1.8	2
555	T follicular helper cells mediate local production of allergen-specific IgE and IgG4. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 1045-1047.	2.9	2
556	Rapid Proliferation of a Different Clone Early after Autologous Peripheral Blood Stem Cell Transplantation for Non-Hodgkin's Lymphoma. <i>International Journal of Hematology</i> , 2002, 76, 287-289.	1.6	1
557	Systemic Lupus Erythematosus and Vasculitis. , 2007, , 310-317.		1
558	Overview of biotherapy in rheumatoid arthritis (RA). <i>Arthritis Research and Therapy</i> , 2012, 14, .	3.5	1

#	ARTICLE	IF	CITATIONS
559	Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. <i>Modern Rheumatology</i> , 2013, , 1.	1.8	1
560	Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 0, , 1.	1.8	1
561	Glomerulomegaly in lupus nephritis: a prognostic marker for renal outcomes. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 768-775.	1.9	1
562	Ground Glass Opacity with Mixed Consolidation on Chest Computed Tomography Reflects the Severe Condition of Pneumocystis Pneumonia in Association with a Poor Prognosis in Patients with Connective Tissue Diseases. <i>Internal Medicine</i> , 2019, 58, 3379-3383.	0.7	1
563	FRIO164â€¦INCIDENCE RATE AND CHARACTERIZATION OF HERPES ZOSTER IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: AN UPDATE FROM BARICITINIB CLINICAL STUDIES. , 2019, , .		1
564	Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and 12â€‰mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan. <i>Modern Rheumatology</i> , 2020, 30, 424-433.	1.8	1
565	Radiographic and clinical effects of 10â€‰mg and 25â€‰mg twice-weekly etanercept over 52 weeks in Japanese patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2021, 31, 319-325.	1.8	1
566	Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease. <i>Rheumatology</i> , 2021, 60, e73-e75.	1.9	1
567	Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis. <i>Modern Rheumatology</i> , 2022, 32, 696-707.	1.8	1
568	Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus. <i>Human Molecular Genetics</i> , 2022, 31, 1082-1095.	2.9	1
569	Suppression of infliximab antibody levels by azathioprine in patients with rheumatoid arthritis. <i>Die Pharmazie</i> , 2017, 72, 95-97.	0.5	1
570	Candida pneumonia in a case of polymyositis complicated with interstitial pneumonitis. <i>Japanese Journal of Rheumatology</i> , 1999, 9, 397-402.	0.0	0
571	Candidapneumonia in a case of polymyositis complicated with interstitial pneumonitis. <i>Japanese Journal of Rheumatology</i> , 1999, 9, 397-402.	0.0	0
572	EA35 Congenital Chagas' disease in Bolivia considered from a result of Xenodiagnosis. <i>Medical Entomology and Zoology</i> , 2001, 52, 139.	0.1	0
573	Interferon Î±-targeted therapy. <i>Japanese Journal of Clinical Immunology</i> , 2013, 36, 181-188.	0.0	0
574	Response to: "When is it not ethical to withhold treatment for rheumatoid arthritis?" by Dr Yusuf Yazici. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e26-e26.	0.9	0
575	4. Progress in Rheumatoid Arthritis Therapy and Future Perspective. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2015, 104, 84a-88a.	0.0	0
576	Tendonitis on the Fingers in Behçet's Disease. <i>Internal Medicine</i> , 2018, 57, 2599-2599.	0.7	0



#	ARTICLE	IF	CITATIONS
595	4. Rheumatic and Collagen-vascular Diseases: Updates on Diagnosis and Treatment. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 486-495.	0.0	0
596	Study on DNA-specific suppressor T cell dysfunction in patients with systemic lupus erythematosus (SLE). Japanese Journal of Clinical Immunology, 1983, 6, 555-560.	0.0	0
597	Pursuit and New Trend in Rheumatoid Arthritis. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 80a-86a.	0.0	0
598	Pursuit and New Trend in Rheumatoid Arthritis. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 1669-1684.	0.0	0
599	2020, 109, 2040-2045.	0.0	0